Divisadero Street Capital Management LP acquired a new position in GeneDx Holdings Corp. (NASDAQ:WGS – Free Report) during the second quarter, Holdings Channel reports. The firm acquired 225,170 shares of the company’s stock, valued at approximately $5,886,000. GeneDx makes up approximately 0.9% of Divisadero Street Capital Management LP’s portfolio, making the stock its 28th biggest holding.
Several other large investors also recently added to or reduced their stakes in WGS. Renaissance Technologies LLC bought a new position in shares of GeneDx in the 2nd quarter worth $2,362,000. American Century Companies Inc. increased its stake in GeneDx by 36.1% in the second quarter. American Century Companies Inc. now owns 17,258 shares of the company’s stock valued at $451,000 after acquiring an additional 4,573 shares during the last quarter. Acadian Asset Management LLC bought a new position in GeneDx in the second quarter valued at $34,000. Rhumbline Advisers raised its position in GeneDx by 8,096.4% during the second quarter. Rhumbline Advisers now owns 18,360 shares of the company’s stock valued at $480,000 after purchasing an additional 18,136 shares in the last quarter. Finally, nVerses Capital LLC bought a new stake in GeneDx during the second quarter worth about $50,000. Institutional investors own 61.72% of the company’s stock.
Insiders Place Their Bets
In other news, CFO Kevin Feeley sold 895 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $33.33, for a total value of $29,830.35. Following the completion of the transaction, the chief financial officer now owns 39,910 shares of the company’s stock, valued at approximately $1,330,200.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, major shareholder Opko Health, Inc. sold 50,000 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $26.63, for a total transaction of $1,331,500.00. Following the sale, the insider now owns 3,508,603 shares of the company’s stock, valued at $93,434,097.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Kevin Feeley sold 895 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $33.33, for a total transaction of $29,830.35. Following the transaction, the chief financial officer now directly owns 39,910 shares of the company’s stock, valued at approximately $1,330,200.30. The disclosure for this sale can be found here. Insiders sold 743,868 shares of company stock worth $24,114,996 over the last three months. Company insiders own 28.10% of the company’s stock.
Analyst Ratings Changes
View Our Latest Stock Report on GeneDx
GeneDx Trading Up 4.8 %
Shares of WGS opened at $40.65 on Friday. The stock has a market capitalization of $1.06 billion, a P/E ratio of -7.85 and a beta of 2.29. The firm has a fifty day simple moving average of $33.36 and a two-hundred day simple moving average of $23.25. The company has a quick ratio of 2.22, a current ratio of 2.38 and a debt-to-equity ratio of 0.27. GeneDx Holdings Corp. has a twelve month low of $1.16 and a twelve month high of $40.92.
GeneDx (NASDAQ:WGS – Get Free Report) last posted its earnings results on Tuesday, July 30th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.15. The company had revenue of $70.51 million during the quarter, compared to analyst estimates of $58.90 million. GeneDx had a negative net margin of 48.21% and a negative return on equity of 22.71%. On average, research analysts anticipate that GeneDx Holdings Corp. will post -0.75 EPS for the current year.
GeneDx Company Profile
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Recommended Stories
- Five stocks we like better than GeneDx
- How to Invest in Small Cap Stocks
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Technology Stocks Explained: Here’s What to Know About Tech
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Want to see what other hedge funds are holding WGS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GeneDx Holdings Corp. (NASDAQ:WGS – Free Report).
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.